JP2008536844A - ニューロトロフィン類似体を用いた細胞生存促進法 - Google Patents

ニューロトロフィン類似体を用いた細胞生存促進法 Download PDF

Info

Publication number
JP2008536844A
JP2008536844A JP2008506498A JP2008506498A JP2008536844A JP 2008536844 A JP2008536844 A JP 2008536844A JP 2008506498 A JP2008506498 A JP 2008506498A JP 2008506498 A JP2008506498 A JP 2008506498A JP 2008536844 A JP2008536844 A JP 2008536844A
Authority
JP
Japan
Prior art keywords
group
substituted
compound
aryl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008506498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008536844A5 (enExample
Inventor
エム ロンゴ フランク
エム マッサ ステフェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of JP2008536844A publication Critical patent/JP2008536844A/ja
Publication of JP2008536844A5 publication Critical patent/JP2008536844A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
JP2008506498A 2005-04-15 2006-04-03 ニューロトロフィン類似体を用いた細胞生存促進法 Pending JP2008536844A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67178505P 2005-04-15 2005-04-15
PCT/US2006/011985 WO2006113097A2 (en) 2005-04-15 2006-04-03 Methods of facilitating cell survival using neurotrophin mimetics

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2012220523A Division JP5586673B2 (ja) 2005-04-15 2012-10-02 ニューロトロフィン類似体を用いた細胞生存促進法
JP2012220524A Division JP5645898B2 (ja) 2005-04-15 2012-10-02 ニューロトロフィン類似体を用いた細胞生存促進法

Publications (2)

Publication Number Publication Date
JP2008536844A true JP2008536844A (ja) 2008-09-11
JP2008536844A5 JP2008536844A5 (enExample) 2009-06-18

Family

ID=37115639

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008506498A Pending JP2008536844A (ja) 2005-04-15 2006-04-03 ニューロトロフィン類似体を用いた細胞生存促進法
JP2012220524A Expired - Lifetime JP5645898B2 (ja) 2005-04-15 2012-10-02 ニューロトロフィン類似体を用いた細胞生存促進法
JP2012220523A Expired - Lifetime JP5586673B2 (ja) 2005-04-15 2012-10-02 ニューロトロフィン類似体を用いた細胞生存促進法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012220524A Expired - Lifetime JP5645898B2 (ja) 2005-04-15 2012-10-02 ニューロトロフィン類似体を用いた細胞生存促進法
JP2012220523A Expired - Lifetime JP5586673B2 (ja) 2005-04-15 2012-10-02 ニューロトロフィン類似体を用いた細胞生存促進法

Country Status (4)

Country Link
US (5) US7723328B2 (enExample)
EP (3) EP2586445A1 (enExample)
JP (3) JP2008536844A (enExample)
WO (1) WO2006113097A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012519703A (ja) * 2009-03-06 2012-08-30 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル ニューロトロフィン・ミメティック及びその使用
CN102740856A (zh) * 2009-11-12 2012-10-17 特罗菲克斯制药股份有限公司 神经营养蛋白模拟化合物及其盐的晶型
JP2017523793A (ja) * 2014-08-07 2017-08-24 ザ ユニバーシティー オブ サセックス アルツハイマー病
US9884833B2 (en) 2012-09-27 2018-02-06 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113097A2 (en) * 2005-04-15 2006-10-26 The University Of North Carolina At Chapel Hill Methods of facilitating cell survival using neurotrophin mimetics
US20110230479A1 (en) * 2005-04-15 2011-09-22 Longo Frank M Neurotrophin mimetics and uses thereof
EP2581440B1 (en) 2005-06-08 2016-03-16 The University of North Carolina At Chapel Hill Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
KR101486026B1 (ko) * 2007-05-10 2015-01-22 도그우드 파마슈티컬스, 아이엔씨. 플루오렌, 안트라센, 잔텐, 디벤조수베론 및 아크리딘의 유도체 및 이의 용도
US20110189310A1 (en) * 2008-10-08 2011-08-04 Cornell University Small molecule modulators of prongf uptake
US20120322799A1 (en) 2009-11-30 2012-12-20 Pharmatrophix, Inc. Deuterated compounds useful for treating neurodegenerative diseases
WO2011156632A2 (en) * 2010-06-09 2011-12-15 Georgetown University Compositions and methods of treatment for tumors in the nervous system
US9828330B2 (en) 2013-03-15 2017-11-28 Pharmatrophix, Inc. Non-peptide BDNF neurotrophin mimetics
CA2901839A1 (en) 2013-03-15 2014-09-18 Pharmatrophix, Inc. Non-peptide bdnf neurotrophin mimetics
EP3412294A1 (en) * 2017-06-08 2018-12-12 Universite De Fribourg Hdac1/2 activator for promoting and/or accelerating myelination and/or remyelination

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996016980A1 (en) * 1994-11-29 1996-06-06 Novartis Ag Morpholinoethylamide derivatives

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743607A (en) 1987-05-29 1988-05-10 Merrell Dow Pharmaceuticals Inc. Cardiotonic tricyclic imidazolones
WO1989010744A1 (en) * 1988-05-02 1989-11-16 Naftchi N Eric Neurologically active compounds
US5028622A (en) * 1988-05-06 1991-07-02 Ajinomoto Company, Inc. Administration of amino acids as treatment for neurodegenerative disorders
US5321029A (en) * 1988-11-14 1994-06-14 Beecham-Wuelfing Gmbh & Co.K.G. Xanthines
CA2010531A1 (en) 1989-03-06 1990-09-06 Werner Neidhart Amino acid derivatives
EP0536671B1 (de) * 1991-10-07 1996-03-06 Hoechst Aktiengesellschaft Carbonsäureester-Schutzgruppen, ein Verfahren zu ihrer Herstellung, ihre Kopplung an eine funktionelle Gruppe sowie ihre Verwendung
US5608067A (en) * 1993-12-09 1997-03-04 Afonso; Adriano 4-substituted pyrazoloquinoline derivatives
GB9402331D0 (en) * 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
JPH08119922A (ja) * 1994-10-21 1996-05-14 Torii Yakuhin Kk ｏ−ピバロイル−チロシン誘導体
JPH1081661A (ja) 1995-10-23 1998-03-31 Sankyo Co Ltd ヒドロキサム酸誘導体
DE69736976T2 (de) * 1996-03-29 2007-10-18 Trustees Of Boston University, Boston Mit Alzheimer Krankheit verknüpften Verfahren zur Diagnose, zur Herstellung von Medikamenten und zum Screenen von Substanzen sowie aus Beta-Amyloid abgeleiteten Peptiden
US5958875A (en) * 1996-03-29 1999-09-28 The Regents Of The University Of California Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity
WO1997042168A1 (en) 1996-05-06 1997-11-13 Zeneca Limited Thio derivatives of hydroxamic acids
GB9715962D0 (en) 1996-08-23 1997-10-01 Zeneca Ltd Sulfonamides
CN1100777C (zh) * 1997-02-19 2003-02-05 伯莱克斯实验室公司 作为nos抑制剂的n－杂环衍生物
FR2762315B1 (fr) * 1997-04-22 1999-05-28 Logeais Labor Jacques Derives d'amino-acides inhibiteurs des metalloproteases de la matrice extracellulaire et de la liberation du tnf alpha
US6117841A (en) * 1997-05-30 2000-09-12 Warner-Lambert Company Substituted peptidylamine calcium channel blockers
AU9064598A (en) * 1998-07-10 2000-02-01 Harald Groger Precusors for pna-monomers
FR2783519B1 (fr) 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
CA2348946A1 (en) * 1998-11-06 2000-05-18 Roche Diagnostics Gmbh Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases
CA2355137A1 (en) * 1998-12-18 2000-06-29 Martyn Clive Pritchard Non-peptide nk1 receptors antagonists
US6583148B1 (en) * 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
US6492380B1 (en) * 1999-05-17 2002-12-10 Queen's University At Kingston Method of inhibiting neurotrophin-receptor binding
US6858577B1 (en) * 1999-06-29 2005-02-22 Ortho-Mcneil Pharmaceutical, Inc. Indole peptidomimetics as thrombin receptor antagonists
DE19939910A1 (de) * 1999-08-23 2001-03-01 Morphochem Ag Neue Verbindungen, die Tryptase-Aktivität hemmen
WO2001042208A1 (en) * 1999-12-08 2001-06-14 Teijin Limited Cycloamine ccr5 receptor antagonists
WO2001052843A1 (en) * 2000-01-18 2001-07-26 Mcgill University β-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS
AR028606A1 (es) * 2000-05-24 2003-05-14 Smithkline Beecham Corp Nuevos inhibidores de mmp-2/mmp-9
US6699989B1 (en) * 2000-08-28 2004-03-02 B. Vithal Shetty Antiviral and antimicrobial guanidine or biguanidine derivatives
AU2002320490B2 (en) * 2001-07-11 2008-10-02 Elan Pharmaceuticals, Inc. N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds
US20040248984A1 (en) * 2001-08-29 2004-12-09 Josef Krieglstein Use of $g(b)-adrenoceptor agonists for the treatment of neurodegenerative diseases
AR039555A1 (es) * 2001-11-08 2005-02-23 Upjohn Co Derivados n,n'-sustituidos de 1,3-diamino-2-hidroxipropano
UA77526C2 (en) * 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
EP1553964A4 (en) 2002-09-25 2009-08-12 Georgia Tech Res Inst KETOAMID INHIBITORS IN CHRONIC NERVE DISEASES
WO2004031145A2 (en) * 2002-10-02 2004-04-15 Bristol-Myers Squibb Company Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor xa inhibitors
US20040186044A1 (en) * 2002-11-06 2004-09-23 Cosgaya Jose Miguel Modulation of myelination by interaction with P75 and TRK receptors
US20050154011A1 (en) * 2003-02-20 2005-07-14 The Procter & Gamble Company Tetrahydroisoquinolnyl sulfamic acids
GB0304433D0 (en) 2003-02-27 2003-04-02 Xceleron Ltd Improvements relating to chemical libraries
WO2005044810A1 (en) * 2003-10-30 2005-05-19 Janssen Pharmaceutica, N.V. Glyt2 modulators
AU2005261487A1 (en) * 2004-07-12 2006-01-19 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide derivatives as inhibitors of histone deacetylase
US20110230479A1 (en) 2005-04-15 2011-09-22 Longo Frank M Neurotrophin mimetics and uses thereof
WO2006113097A2 (en) 2005-04-15 2006-10-26 The University Of North Carolina At Chapel Hill Methods of facilitating cell survival using neurotrophin mimetics
EP2581440B1 (en) * 2005-06-08 2016-03-16 The University of North Carolina At Chapel Hill Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
EP1962855B1 (en) * 2005-12-22 2013-08-21 Hydra Biosciences, Inc. Trpa1 inhibitors for treating pain
WO2008107365A1 (en) 2007-03-02 2008-09-12 Medivir Ab New compounds
CA2754570A1 (en) 2009-03-06 2010-09-10 The University Of North Carolina At Chapel Hill Neurotrophin mimetics and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996016980A1 (en) * 1994-11-29 1996-06-06 Novartis Ag Morpholinoethylamide derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5008003964; Ｊ　Ａｌｚｈｅｉｍｅｒ'ｓ　Ｄｉｓｅａｓｅ Ｖｏｌ．６, 2004, ｐｐ．Ｓ１３-７ *
JPN6011050522; Ｊ　Ｐｒａｋｔｉｓｃｈｅ　Ｃｈｅｍｉｅ Ｖｏｌ．１２, 1961, ｐｐ．２１２-４ *
JPN6011050523; Ｊ　Ｍｅｄ　Ｃｈｅｍ Ｖｏｌ．４３, 2000, ｐｐ．２１００-１４ *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012519703A (ja) * 2009-03-06 2012-08-30 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル ニューロトロフィン・ミメティック及びその使用
CN108383804A (zh) * 2009-11-12 2018-08-10 特罗菲克斯制药股份有限公司 神经营养蛋白模拟化合物及其盐的晶型
JP2013510874A (ja) * 2009-11-12 2013-03-28 ファーマトロフィックス， インコーポレイテッド ニューロトロフィン模倣化合物およびこれらの塩の結晶形態
CN102740856B (zh) * 2009-11-12 2015-02-18 特罗菲克斯制药股份有限公司 神经营养蛋白模拟化合物及其盐的晶型
JP2016020380A (ja) * 2009-11-12 2016-02-04 ファーマトロフィックス， インコーポレイテッド ニューロトロフィン模倣化合物およびこれらの塩の結晶形態
US9271986B2 (en) 2009-11-12 2016-03-01 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
JP2018115218A (ja) * 2009-11-12 2018-07-26 ファーマトロフィックス， インコーポレイテッド ニューロトロフィン模倣化合物およびこれらの塩の結晶形態
CN102740856A (zh) * 2009-11-12 2012-10-17 特罗菲克斯制药股份有限公司 神经营养蛋白模拟化合物及其盐的晶型
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US10532988B2 (en) 2009-11-12 2020-01-14 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US11225467B2 (en) 2009-11-12 2022-01-18 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US9884833B2 (en) 2012-09-27 2018-02-06 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
JP2017523793A (ja) * 2014-08-07 2017-08-24 ザ ユニバーシティー オブ サセックス アルツハイマー病

Also Published As

Publication number Publication date
EP1871420A2 (en) 2008-01-02
EP2594318B1 (en) 2020-06-10
US8916556B2 (en) 2014-12-23
US20170157127A1 (en) 2017-06-08
JP5586673B2 (ja) 2014-09-10
EP1871420A4 (en) 2010-09-22
US20110003819A1 (en) 2011-01-06
US20100267727A1 (en) 2010-10-21
EP2594318A1 (en) 2013-05-22
US7723328B2 (en) 2010-05-25
JP2013032373A (ja) 2013-02-14
JP2013047236A (ja) 2013-03-07
JP5645898B2 (ja) 2014-12-24
EP2586445A1 (en) 2013-05-01
WO2006113097A3 (en) 2007-03-15
WO2006113097A2 (en) 2006-10-26
US20150111903A1 (en) 2015-04-23
US20060246072A1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
JP5586673B2 (ja) ニューロトロフィン類似体を用いた細胞生存促進法
JP5461009B2 (ja) 非ペプチド及びペプチドｂｄｎｆニューロトロフィン類似体を用いた神経細胞生存促進法
US20120004310A1 (en) Non-peptide bdnf neurotrophin mimetics
US20140100224A1 (en) Neurotrophin mimetics and uses thereof
JP2016026142A (ja) ニューロトロフィン・ミメティック及びその使用
US20170348255A1 (en) Methods of treating prader-willi syndrome
CA3192701A1 (en) Use of sphingosine-1-phosphate receptor agonist
US9828332B2 (en) Non-peptide BDNF neurotrophin mimetics
US20080312253A1 (en) Pharmaceutical compositions containing pyrazole derivatives for treating as serotonin antagonist
US20210393606A1 (en) Therapeutic agent for frontal lobe dysfunction
JP2005239712A (ja) 神経突起伸展剤
HK1178067B (en) Methods of facilitating neural cell survival using non-peptide and peptide bdnf neurotrophin mimetics
HK1178067A (en) Methods of facilitating neural cell survival using non-peptide and peptide bdnf neurotrophin mimetics
HK1249059B (en) Therapeutic agent for frontal lobe dysfunction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090402

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111221

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120124

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120827

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120926

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121003

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130115